<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162185</url>
  </required_header>
  <id_info>
    <org_study_id>MaxPlanckHCBS</org_study_id>
    <nct_id>NCT03162185</nct_id>
  </id_info>
  <brief_title>Serotonin and Motor Plasticity</brief_title>
  <official_title>The Effects of Serotonergic Challenge on Motor Learning and Neuroplasticity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Max Planck Institute for Human Cognitive and Brain Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Max Planck Institute for Human Cognitive and Brain Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this study, the investigators aim to test whether acute administration of selective
      serotonin reuptake inhibitors (SSRI) improves motor performance in a sequential motor
      learning task in comparison to placebo in healthy humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Microdialysis findings in animal models provide evidence for a monoaminergic augmentation of
      motor function. However, this evidence is largely limited to noradrenaline and dopamine, with
      little evidence to support a similar effect for serotonin. What remains to be tested
      therefore, is whether acute serotonergic administration induces neural or behavioral changes
      during motor learning also. Using a sample of 60 female participants (with the possible
      inclusion of male participants at a later date), the investigators aim to test the effects of
      a serotonergic challenge on motor learning and plasticity in healthy participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">November 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pinch Force Task.</measure>
    <time_frame>1 week</time_frame>
    <description>The primary outcome measure will be reaction time and accuracy of motor responses, as measured by the Pinch Force Task. This will be applied to both the experimental (SSRI) and control (Placebo) groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Controls</condition>
  <arm_group>
    <arm_group_label>Interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half of the participants (n = 30) will receive 20mg of the SSRI Escitalopram.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Half of the participants ( n= 30) will receive the placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.</description>
    <arm_group_label>Interventional group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Control group participants (n = 30) will receive a placebo for 7 days.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female

          -  right-handed

          -  healthy

          -  has taken oral contraceptives (ovulation inhibitor) continuously for at least 3 months

          -  has read and agreed to study parameters

        Exclusion Criteria:

          -  tattoos on head or neck

          -  non-removable metal on or in body

          -  alcohol abuse

          -  is currently taking medication

          -  smokes more than 3 cigarettes per day

          -  positive drug test

          -  pregnancy

          -  plays an instrument professionally

          -  plays videogames more than 2 hours per week

          -  is a professional athlete

          -  suffers from migraines

          -  has taken part in another study, where motor learning skills and/or medication is a
             factor, in the last 3 months

          -  heart rhythm disorders (long QT)

          -  hypertension

          -  calcium or magnesium deficiency

          -  neurological disorders

          -  chronic metabolic disorders

          -  liver or kidney diseases

          -  immunodeficiency

          -  endocrine disorders

          -  psychiatric disorders

          -  tumors

          -  injuries to the head and brain
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arno Villringer</last_name>
    <role>Study Chair</role>
    <affiliation>Max Planck Institute for Human Cognitive and Brain Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia Sacher</last_name>
    <role>Study Director</role>
    <affiliation>Max Planck Institute for Human Cognitive and Brain Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alyson Buchenau</last_name>
    <phone>+49-341-9940-2216</phone>
    <email>buchenau@cbs.mpg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eoin Molloy</last_name>
    <phone>+49 341 9940-2555</phone>
    <email>molloy@cbs.mpg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Max Planck Institute for Cognition and Brain Sciences</name>
      <address>
        <city>Leipzig</city>
        <state>Saxony</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyson Buchenau</last_name>
      <phone>+49-0341-9940-2216</phone>
      <email>buchenau@cbs.mpg.de</email>
    </contact>
    <contact_backup>
      <last_name>Eoin Molloy</last_name>
      <phone>+49 341 9940-2555</phone>
      <email>molloy@cbs.mpg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuroplasticity</keyword>
  <keyword>SSRI</keyword>
  <keyword>Motor Learning</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

